Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 27, Issue 1, 2008, Pages 35-42

  Thong, Patricia S P ^a   Olivo, Malini ^a   Kho, Kiang Wei ^a   Bhuvaneswari, Ramaswamy ^a   Chin, William W L ^a   Ong, Kong Wee ^a   Soo, Khee Chee ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Angiosarcoma; Drug dose; Fluence rate; Immune response; Light dose; Photodynamic therapy; Treatment regimes

Indexed keywords

FOTOLON; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADULT; ANGIOSARCOMA; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CELLULAR IMMUNITY; DOSIMETRY; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IRRADIATION; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 41949142904     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i1.40     Document Type: Article

References (17)

1. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Nat Ca Inst. 1998;90(12):889-905.
2. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380-7.
3. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumor immunity. Nat Rev Cancer. 2006;6:535-45.
4. Du HY, Bay BH, Olivo M. Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model. Int J Oncol. 2003;22(5):1019-24.
5. Thong PS, Watt F, Ren MQ, Tan PH, Soo KC, Olivo M. Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT. J Photochem Photobiol B. 2006;82(1):1-8.
6. Wyld L, Reed MW, Brown NJ. Differential cell death response to PDT is dependent on dose and cell type. Br J Cancer. 2001;84(10):1384-6.
7. Kamuhabwa AR, Agostinis PM, D'Hallewin MA, Baert L, de Witte PA. Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol. 2001;74(2):26-132.
8. Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2001;64(6):2120-6.
9. Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med. 2006 Jun;38(5):489-93.
10. Chin WW, Heng PW, Bhuvaneswari R, Lau WK, Olivo M. The potential application of chlorin e6-polyvinylpyrrolidone formulation in photodynamic therapy. Photochem Photobiol Sci. 2006;5(11):1031-7.
11. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400-6.
12. McIntosh BC, Narayan D. Head and neck angiosarcomas. J Craniofac Surg. 2005;16(14):699-703.
13. Thong PSP, Ong KW, Goh NSG, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC. Photodynamic therapy-activated immune response against distant untreated lesions in recurrent angiosarcoma. Lancet Oncol. 2007;8(10):950-2.
14. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 1996;56(24):5647-52.
15. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen K, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN, Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61(1):192-6.
16. Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg Med. 2006;38(5):509-15.
17. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med. 2006;38(5):500-8.